|本期目录/Table of Contents|

[1]史小可,李晟,付乃洁,等.腺苷酸环化酶抑制剂体外筛选模型的建立及应用[J].应用与环境生物学报,2021,27(01):185-190.[doi:10.19675/j.cnki.1006-687x.2020.01047]
 SHI Xiaoke,LI Sheng,et al.Establishment and application of a screening model of adenylate cyclase inhibitor in vitro[J].Chinese Journal of Applied & Environmental Biology,2021,27(01):185-190.[doi:10.19675/j.cnki.1006-687x.2020.01047]
点击复制

腺苷酸环化酶抑制剂体外筛选模型的建立及应用()
分享到:

《应用与环境生物学报》[ISSN:1006-687X/CN:51-1482/Q]

卷:
27卷
期数:
2021年01期
页码:
185-190
栏目:
研究论文
出版日期:
2021-02-25

文章信息/Info

Title:
Establishment and application of a screening model of adenylate cyclase inhibitor in vitro
作者:
史小可李晟付乃洁曹东怡王飞
1中国科学院成都生物研究所天然产物中心 成都 610041 2中国科学院大学 北京 100049
Author(s):
SHI Xiaoke1 2 LI Sheng1 2 FU Naijie1 2 CAO Dongyi1 2 & WANG Fei1 2?
1 Center for Natural Products Research, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China 2 University of Chinese Academy of Sciences, Beijing 100049, China
关键词:
腺苷酸环化酶雌激素生物合成芳香化酶卵巢颗粒细胞
Keywords:
adenylate cyclase estrogen biosynthesis aromatase ovarian granulosa cell
DOI:
10.19675/j.cnki.1006-687x.2020.01047
摘要:
腺苷酸环化酶(adenylate cyclase,AC)通过调节环磷酸腺苷(cyclic adenosine cyclophosphate,cAMP)的合成从而调控细胞相关功能. 在卵巢中,cAMP调控卵母细胞的发育及卵子的成熟,cAMP含量变化影响下游芳香化酶的表达,进而影响雌激素的生物合成. 为开发靶向AC的候选药物,根据AC1、AC2两个活性区域,利用大肠杆菌系统克隆表达可溶IC1- IIC2重组融合蛋白,使用ATP检测试剂盒,检测IC1-IIC2 的催化活性,从而建立有效的IC1-IIC2蛋白体外筛选抑制剂模型. 利用该模型筛选了由2 861个化合物组成的文库. 化合物来那替尼(neratinib)可明显抑制IC1-IIC2蛋白活性,且呈浓度依赖性,其IC50为10.2 ± 0.152 2 μmol/L. 进一步研究发现,来那替尼可显著降低人卵巢颗粒细胞KGN细胞中芳香化酶的表达,并且抑制雌激素的生物合成. 本研究通过建立蛋白体外筛选模型发现来那替尼具有抑制AC的活性,结果可为开发新的靶向芳香化酶治疗多囊卵巢综合征等疾病的候选药物提供参考. (图5 表1 参28)
Abstract:
Adenylate cyclase (AC) affects cellular functions by regulating the synthesis of cyclic adenosine monophosphate (cAMP), which regulates oocyte development and follicle maturation in the ovary. Changes in cAMP content modulates the expression of aromatase and the biosynthesis of estrogen. Therefore, inhibition of AC by small molecules may provide new therapeutic means for the treatment of estrogen-related diseases. In order to develop candidate drugs targeting AC, an Escherichia coli system was used to clone and express soluble IC1-IIC2 recombinant fusion proteins based on the two active regions of AC1 and AC2. The catalytic activity of IC1-IIC2 was evaluated using an ATP detection kit. A chemical library consisting of 2 861 compounds was screened for inhibitors of IC1-IIC2. The results showed that the compound neratinib significantly inhibited IC1-IIC2 activity in a concentration-dependent manner, with an IC50 value of 10.2 ± 0.1522 μmol/L. Furthermore, neratinib significantly inhibited the expression of aromatase and the biosynthesis of estrogen in human ovarian granulose-like KGN cells. This study established a high-throughput screening model of IC1-IIC2 protein to find a highly active AC inhibitor in vitro, providing a good experimental foundation for the study of infertility treatment.

参考文献/References:

1 Steegborn C. Structure, mechanism, and regulation of soluble adenylyl cyclases-similarities and differences to transmembrane adenylyl cyclases [J]. Biochim Biophys Acta, 2014, 1842 (12 Pt B): 2535-2547
2 Halls ML, Cooper DMF. Adenylyl cyclase signalling complexes-pharmacological challenges and opportunities [J]. Pharmacol Ther, 2017, 172: 171-180
3 Pierre S, Eschenhagen T, Geisslinger G, Scholich K. Capturing adenylyl cyclases as potential drug targets [J]. Nat Rev Drug Discov, 2009, 8 (4): 321-335
4 Sinha SC, Sprang SR. Structures, mechanism, regulation and evolution of class III nucleotidyl cyclases [J]. Rev Physiol Biochem Pharmacol, 2006, 157: 105-140
5 Guo YH, Liang XY, Yu SY, Hao DD, Yang HY, Gao ZY, Xu RQ. Expression and function of adenylate cyclase in mammals [J]. Chin J Cell Biol, 2018, 40 (3): 426-438
6 Wang H, Zhang M. The role of Ca2+-stimulated adenylyl cyclases in bidirectional synaptic plasticity and brain function [J]. Rev Neurosci, 2012, 23 (1): 67-78
7 Rana N, Conley JM, Soto-Velasquez M, León F, Cutler SJ, Watts VJ, Lill MA. Molecular modeling evaluation of the enantiomers of a novel adenylyl cyclase 2 inhibitor [J]. J Chem Inf Model, 2017, 57 (2): 322-334
8 Mehlmann LM. Stops and starts in mammalian oocytes: recent advances in understanding the regulation of meiotic arrest and oocyte maturation [J]. Reproduction, 2005, 130 (6): 791-799
9 Webb RJ, Marshall F, Swannb K, Carrolla J. Follicle-stimulating hormone induces a gap junction-dependent dynamic change in cAMP and protein kinase a in mammalian oocytes [J]. Dev Biol, 2002, 246 (2): 441-454
10 Sun QY, Miao YL, Schatten H. Towards a new understanding on the regulation of mammalian oocyte meiosis resumption [J]. Cell Cycle, 2009, 8 (17): 2741-2747
11 Wang XY, Simpson ER, Brown KA. Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer [J]. J Steroid Biochem Mol Biol, 2015, 153: 35-44
12 Richards JS, Russell DL, Ochsner S, Hsieh M, Doyle KH, Falender AE, Lo YK, Sharma SC. Novel signaling pathways that control ovarian follicular development, ovulation, and luteinization [J]. Recent Prog Horm Res, 2002, 57: 195-220
13 Seifert R, Lushington GH, Mou TC, Gille A, Sprang SR. Inhibitors of membranous adenylyl cyclases [J]. Cell, 2012, 3: 64-78
14 Zhang D, Deng ZH, Tan J, Liu SR, Hu SY, Tao H, Tang RH. All-trans retinoic acid stimulates thesecretion of TGF-β2 via the phospholipase C but not the adenylyl cyclase signalingpathway in retinal pigment epithelium cells [J]. BMC Ophthalmol, 2019, 19 (23): 1-6
15 Wang H, Xu H, Wu LJ, Kim SS, Chen T, Koga K, Descalzi G, Gong B, Vadakkan KI, Zhang XH, Kaang BK, Zhuo M. Identification of an adenylyl cyclase inhibitor for treating neuropathic and inflammatory pain [J]. Sci Transl Med, 2011, 3 (65): 65ra63
16 Fabbro D, Ruetz S, Buchdunger E, WCowan-Jacob S, Fendrich G, Liebetanz J, Mestan J, O’Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Wmanley P. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs [J]. Pharmacol Ther, 2002, 93 (2-3): 79-98
17 Tai ZF, Zhang GL, Wang F. Identification of small molecule activators of the Janus kinase/signal transducer and activator of transcription pathway using a cell-based screen [J]. Biol Pharm Bull, 2012, 35 (1): 65-71
18 邓腾, 杨莉娟, 罗国勇, 李晟, 杜宝文, 王飞. 蛋白酪氨酸磷酸酶SHP2抑制剂体外筛选模型的建立及应用[J]. 应用与环境生物学报,2015, 21 (4): 602-606 [Deng T, Yang LJ, Luo GY, Li S, Du BW, Wang F. Establishment and application of in vitro screening platform for inhibitors of protein tyrosine phosphate SHP2 [J]. Chin J Appl Environ Biol, 2015, 21 (4): 602-606]
19 史楠, 史小可, Bahtigul JA, Anvar A, Alisher R, 王飞. Eryxin通过抑制芳香化酶表达调控雌激素生物合成[J]. 应用与环境生物学报, 2019, 25 (5): 1205-1210 [Shi N, Shi XK, Jovliqizi AB, Abduvaliev A, Rakhmanov A, Wang F. Eryxin inhibits estrogen biosynthesis by suppression of aromatase [J]. Chin J Appl Environ Biol, 2019, 25 (5): 1205-1210]
20 Sun Z, Zhang W, Xue X, Zhang Y, Niu R, Li X, Li B, Wang X, Wang J. Fluoride decreased the sperm ATP of mice through inhabiting mitochondrial respiration [J]. Chemosphere, 2016, 144: 1012-1017
21 Kang WB, Yang Q, Guo YY, Wang L, Wang DS, Cheng Q, Li XM, Tang J, Zhao JN, Liu G, Zhuo M, Zhao MG. Analgesic effects of adenylyl cyclase inhibitor NB001 on bone cancer pain in a mouse model [J]. Mol Pain, 2016, 12: 1-9
22 Ahujaa M, Jhaa A, Malétha J, Parkb S, Muallem S. cAMP and Ca2+ signaling in secretory epithelia: crosstalk and synergism [J]. Cell Calcium, 2014, 55 (6): 385-393
23 Morinaga H, Yanase T, Nomura M, Okabe T, Goto K, Harada N, Nawata H. A benzimidazole fungicide, benomyl, and its metabolite, carbendazim, induce aromatase activity in a human ovarian granuloselike tumor cell line (KGN) [J]. Endocrinology, 2004, 145 (4): 1860-1869
24 Thompson Jr EA, Siiteri PK. The involvement of human placental microsomal cytochrome P-450 in aromatization [J]. J Biol Chem, 1974, 249: 5373-5378
25 Woodruff TK, Shea LD. The role of the extracellular matrix in ovarian follicle development [J]. Reprod Sci, 2007, 14 (s8): 6-10
26 Dienstmann R, Dosso DS, Felip E, Tabernero P. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer [J]. Mol Oncol, 2012, 6 (1): 15-26
27 Singh H, Walker AJ, Amiri-Kordestani L, Cheng J, Tang SH, Balcazar P, Barnett-Ringgold K, Palmby TR, Cao XH, Zheng N, Liu Q, Yu JY, Pierce WF, Daniels SR, Sridhara R, Ibrahim A, Kluetz PG, Blumenthal GM, Beaver JA, Pazdur R.US. Food and drug administration approval: neratinib for the extended adjuvant treatment of early-stage HER2-positive breast cancer [J]. Clin Cancer Res, 2018, 24 (15): 3486-3491
28 Castoria1 C, Migliaccio A, D’Amato L, Stasio RD, Ciociola A, Lombardi M, Bilancio A, Domenico MD, De-Falco A, Auricchio F. Integrating signals between cAMP and MAPK pathways in breast cancer [J]. Front Biosci, 2008, 13: 1318-1327

更新日期/Last Update: 2021-02-25